Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes

被引:18
|
作者
Riner, Andrea N. [1 ]
Underwood, Patrick W. [1 ]
Yang, Kai [2 ]
Herremans, Kelly M. [1 ]
Cameron, Miles E. [1 ,3 ]
Chamala, Srikar [4 ]
Qiu, Peihua [2 ]
George, Thomas J. [5 ]
Permuth, Jennifer B. [6 ,7 ]
Merchant, Nipun B. [8 ]
Trevino, Jose G. [1 ]
机构
[1] Univ Florida, Dept Surg, Coll Med, 1600 SW Archer Rd,POB 100109, Gainesville, FL 32610 USA
[2] Univ Florida, Dept Biostat, Coll Med, Gainesville, FL 32610 USA
[3] Univ Florida, Dept Phys Therapy, Coll Med, Gainesville, FL 32610 USA
[4] Univ Florida, Dept Pathol Immunol & Lab Med, Coll Med, Gainesville, FL 32610 USA
[5] Univ Florida, Dept Med, Coll Med, Div Hematol & Oncol, Gainesville, FL 32610 USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL USA
[7] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA
[8] Univ Miami, Coll Med, Dept Surg, Miami, FL USA
来源
CANCER MEDICINE | 2020年 / 9卷 / 12期
基金
美国国家卫生研究院;
关键词
pancreatic ductal adenocarcinoma; survival; RACIAL DISPARITIES; CANCER; SURVIVAL;
D O I
10.1002/cam4.3042
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Disparities exist among patients with pancreatic ductal adenocarcinoma (PDAC). Non-White race is regarded as a negative predictor of expected treatment and overall survival. Data suggest that Academic Research Programs (ARP) provide better outcomes for minorities, but ethnic/minority outcomes are underreported. We hypothesize that outcomes among racially/ethnically diverse PDAC patients may be influenced by treatment facility. Methods The National Cancer Database was used to identify 170,327 patients diagnosed with PDAC between 2004 and 2015. Cox proportional-hazard regression was used to compare survival between race/ethnic groups across facilities. Results In unadjusted models, compared to non-Hispanic Whites (NHW), non-Hispanic Blacks (NHB) had the worst overall survival (HR = 1.05, 95%CI: 1.03-1.06, P < .001) and Hispanics had the best overall survival (HR = 0.92, 95%CI: 0.90-0.94, P < .001). After controlling for socioeconomic and clinical covariates, NHB (HR = 0.95, 95%CI: 0.93-0.96, P < .001) had better overall survival compared to NHW, and Hispanics continued to have the best comparative outcomes (HR = 0.84, 95%CI: 0.82-0.86, P < .001). Among Hispanics, Dominicans and South/Central Americans lived the longest, at 10.25 and 9.82 months, respectively. The improved survival in Hispanics was most pronounced at ARP (HR = 0.80, 95%CI: 0.77-0.84, P < .001) and Integrated Network Cancer Programs (HR = 0.78, 95%CI: 0.73-0.84, P < .001). NHB had improved survival over NHW at Comprehensive Community Care Programs (HR = 0.96, 95%CI: 0.93-0.98, P = .002) and ARP (HR = 0.96, 95%CI: 0.94-0.98, P = .001), which was influenced by income, education, and surgical resection. Conclusion Survival was improved at ARP for all populations. Hispanics had the best comparative overall survival. NHB had improved overall survival at higher volume centers, but this was dependent upon income, education, and surgical resection.
引用
收藏
页码:4069 / 4082
页数:14
相关论文
共 50 条
  • [31] Hispanics have improved overall survival with pancreatic ductal adenocarcinoma regardless of treatment facility
    Riner, Andrea N.
    Underwood, Patrick
    Yang, Kai
    Chamala, Srikar
    Qiu, Peihua
    Trevino, Jose G.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [32] Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity
    Swords, Douglas S.
    Mulvihill, Sean J.
    Brooke, Benjamin S.
    Skarda, David E.
    Firpo, Matthew A.
    Scaife, Courtney L.
    SURGERY, 2019, 165 (04) : 751 - 759
  • [33] Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison to pancreatic ductal adenocarcinoma
    Huang, Xing
    Li, Mao
    Zhang, Ling
    Xiong, Junjie
    Lu, Huimin
    Tian, Bole
    SURGICAL ONCOLOGY-OXFORD, 2021, 37
  • [34] Association of Mutant KRAS Alleles With Morphology and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma
    Chao, Timothy
    Wang, Zi-Xuan
    Bowne, Wilbur B.
    Yudkoff, Clifford J.
    Torjani, Ava
    Swaminathan, Vishal
    Kavanagh, Taylor R.
    Roadarmel, Austin
    Sholevar, Cyrus J.
    Cannaday, Shawnna
    Krampitz, Geoffrey
    Zhan, Tingting
    Gorgov, Eliyahu
    Nevler, Avinoam
    Lavu, Harish
    Yeo, Charles J.
    Peiper, Stephen C.
    Jiang, Wei
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (12) : 1299 - 1309
  • [35] Cell Type of Pancreatic Ductal Adenocarcinoma Origin: Implications for Prognosis and Clinical Outcomes
    Patil, Shilpa
    Dou, Yan
    Kopp, Janel L.
    VISCERAL MEDICINE, 2022, 38 (01) : 4 - 10
  • [36] Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC)
    Yin, Han
    Romero-Hernandez, Fernanda
    Ganjouei, Amir Ashraf
    Wang, Jaeyun Jane
    Brown, Audrey
    Hirose, Kenzo
    Maker, Ajay V.
    Nakakura, Eric
    Corvera, Carlos
    Kirkwood, Kimberly S.
    Wilhelm, Alexander
    Peng, June S.
    Alseidi, Adnan
    Adam, Mohamed A.
    CURRENT ONCOLOGY, 2024, 31 (09) : 5008 - 5020
  • [37] Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma
    Kim, Hyemin
    Heo, Chan Mi
    Oh, Jinmyeong
    Chung, Hwe Hoon
    Lee, Eun Mi
    Park, Juhee
    Lee, Se-Hoon
    Lee, Kwang Hyuck
    Lee, Kyu Taek
    Lee, Jong Kyun
    Cho, Yoon-Kyoung
    Park, Joo Kyung
    TRANSLATIONAL ONCOLOGY, 2022, 16
  • [38] Clinical Significance of Serum Col6a3 Isoforms in Pancreatic Ductal Adenocarcinoma
    Kang, Christopher Y.
    Axell-House, Dierdre
    Soni, Pranay
    Chipitsyna, Galina
    Sarosiek, Konrad
    Al-Zoubi, Mazhar
    Arafat, Hwyda A.
    Yeo, Charles J.
    GASTROENTEROLOGY, 2013, 144 (05) : S1045 - S1045
  • [39] Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma
    Chang, Ming-Chu
    Chang, Yu-Ting
    Chen, Jia-Yang
    Jeng, Yung-Ming
    Yang, Ching-Yao
    Tien, Yu-Wen
    Yang, Shih-Hung
    Chen, Huai-Lu
    Liang, Ting-Yuan
    Wang, Chien-Fang
    Lee, Eva Y. H. P.
    Chang, Ying-Chih
    Lee, Wen-Hwa
    CLINICAL CHEMISTRY, 2016, 62 (03) : 505 - 513
  • [40] Clinical Significance of Serum COL6A3 in Pancreatic Ductal Adenocarcinoma Discussion
    Ahmad, Syed
    Kang, Christopher
    JOURNAL OF GASTROINTESTINAL SURGERY, 2014, 18 (01) : 15 - 15